J Pfisterer


Affiliation: University of Kiel
Country: Germany


  1. request reprint
    Pfisterer J, Hilpert F, Du Bois A, Meier W, Wagner U. State-of-the-art first-line treatment of ovarian cancer. Onkologie. 2003;26:446-50 pubmed
    ..All items are discussed in detail. ..
  2. request reprint
    Pfisterer J, Harter P, Canzler U, Richter B, Jackisch C, Hahmann M, et al. The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15 Suppl 3:195-8 pubmed
    ..83; 95% CI: 1.16-2.88; P= 0.009). Only patients with complete resection seem to benefit from CS. This new panel of selection criteria will be evaluated in a prospective study. ..
  3. request reprint
    Pfisterer J, Du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol. 2006;17:1568-77 pubmed
    ..Abagovomab s.c. vaccination is safe and well tolerated. The long vaccination schedule tended to be more effective with regard to AB3-induction and cellular cytotoxicity. ..